Oraxol: Phase I start

Next month, Kinex and partner Zenith Technology Ltd. (Dunedin, New Zealand) will begin an open-label, crossover, New Zealand Phase I trial to compare 270 mg oral Oraxol vs. IV paclitaxel in 8 cancer p...